HHS Will Study Generic Approval Process; McCain Sets Hearing For May 17
Executive Summary
HHS Secretary Thompson's review of FDA will include an examination of the generic drug approval process, Thompson told a House Energy & Commerce/Health Subcommittee hearing.
You may also be interested in...
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials